Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday

Tourmaline Bio (NASDAQ:TRML - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Tourmaline Bio to post earnings of ($0.91) per share for the quarter.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tourmaline Bio Price Performance

NASDAQ:TRML traded down $0.65 during mid-day trading on Friday, reaching $15.09. The stock had a trading volume of 287,554 shares, compared to its average volume of 271,269. The company has a market capitalization of $387.59 million, a price-to-earnings ratio of -5.35 and a beta of 2.11. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The stock's 50 day simple moving average is $15.49 and its two-hundred day simple moving average is $18.78.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TRML shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a report on Monday, May 5th. Chardan Capital reiterated a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Wedbush raised their price target on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. Finally, Lifesci Capital initiated coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They set an "outperform" rating and a $58.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Tourmaline Bio currently has an average rating of "Buy" and a consensus price target of $49.33.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.